---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020075"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:40:53.012186+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics Q1 net loss $63.9M on impairment charges; new CEO/CFO

## Summary
- Net loss of $63.9M in Q1 2023 vs $24.6M in Q1 2022; includes $32.9M IPR&D impairment and $13.1M long-lived asset impairment.
- Cash and equivalents $41.7M as of Mar 31, 2023; expects to fund operations into 2025.
- Clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 in ulcerative colitis; topline data expected in 2025.
- Executive leadership transition: Matthew Blischak to become CEO, Lance Thibault to become CFO effective May 16, 2023.
- Safety analysis from discontinued PRISM4 trial showed no drug-related serious adverse events among 19 patients.

## SEC filing metadata
- accession: 0000950170-23-020075
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017023020075/0000950170-23-020075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017023020075/fnch-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020075
- JSON: https://secwatch.observer/filing/0000950170-23-020075.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020075.txt

## Key facts
- Earnings Releases
  Finch Therapeutics Group, Inc. reported first quarter of 2023 results: net income net loss of $63.9 million.
  - Period: first quarter of 2023
  - Net income: net loss of $63.9 million
  - Result: reported results
  source text: Finch reported a net loss of $63.9 million for the first quarter of 2023, compared to a net loss of $24.6 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000095017023020075/0000950170-23-020075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.